a Department of Infectious Diseases , The First Affiliated Hospital, Anhui Medical University , Hefei , P.R. China.
b Department of Nephrology , The First Affiliated Hospital, Anhui Medical University , Hefei , P.R. China.
Pharm Biol. 2017 Dec;55(1):2178-2187. doi: 10.1080/13880209.2017.1390589.
Total glucosides of peony (TGP), compounds extracted from the dried roots of Paeonia lactiflora Pall, have been reported to have anti-inflammatory and antioxidative activities. However, the protective effect of TGP on liver injury and the underlying mechanisms remains unknown in diabetic rats.
Current study investigates prevention of liver injury by TGP in diabetic rats and its mechanism was related to the inhibition of endoplasmic reticulum stress (ERS).
Fifty adult male rats were randomly divided into: Normal group, diabetic group, TGP (50, 100 and 200 mg/kg/day) treatment groups (n = 10 per group). At the end of the 8th week, the liver was removed for biochemical and histological examinations.
Compared with the diabetic group, administration of TGP at doses of 50, 100 and 200 mg/kg significantly prevented the increase of hepatic fibrosis score (ED 139.4 mg/kg). Compared with diabetic group, TGP at doses of 50, 100 and 200 mg/kg showed an inhibition on the increased macrophage infiltration. MCP-1 and TNF-α mRNA and protein expression were significantly increased in diabetic group compared with normal group; TGP administration caused significant reduction of high levels of MCP-1 and TNF-α mRNA as well as protein levels. Also, TGP at all doses showed an inhibition on the increased GRP78 levels, p-Perk levels and p-Eif2α levels in liver from diabetic group.
Our results indicate that TGP has potential as a treatment for diabetic liver injury attenuating liver lipid accumulation and inflammation as well as ERS induced by diabetic condition.
白芍总苷（TGP）是从白芍干燥根中提取的化合物，具有抗炎和抗氧化作用。然而，TGP 对糖尿病大鼠肝损伤的保护作用及其机制尚不清楚。
本研究探讨 TGP 对糖尿病大鼠肝损伤的预防作用及其机制与抑制内质网应激（ERS）有关。
50 只成年雄性大鼠随机分为：正常组、糖尿病组、TGP（50、100 和 200mg/kg/天）治疗组（每组 10 只）。第 8 周末，取出肝脏进行生化和组织学检查。
与糖尿病组相比，TGP 50、100 和 200mg/kg 剂量组可显著防止肝纤维化评分增加（ED139.4mg/kg）。与糖尿病组相比，TGP 50、100 和 200mg/kg 剂量组可显著抑制巨噬细胞浸润增加。与正常组相比，糖尿病组 MCP-1 和 TNF-αmRNA 和蛋白表达明显增加；TGP 给药可显著降低 MCP-1 和 TNF-αmRNA 及蛋白水平的升高。此外，TGP 各剂量组均能抑制糖尿病组肝组织中 GRP78 水平、p-Perk 水平和 p-Eif2α 水平的升高。
我们的结果表明，TGP 具有治疗糖尿病肝损伤的潜力，可减轻糖尿病状态引起的肝脂质积累、炎症和 ERS。
